Tempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million Genomes

{
  "signal_id": "31782075-ab16-af29-be71-17c0ead894ef",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-19T11:14:21+00:00",
  "company": {
    "name": "Tempus AI",
    "domain": "tempus.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/tempus-ai-tem-unveils-whole-111421978.html",
    "title": "Tempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million Genomes - finance.yahoo.com",
    "excerpt": "Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a wider backdrop our research has uncovered. Take a look at 2 warning signs we have identified for Tempus AI. Zooming out from Tempus AI, the push to pair genomics with real-world data is reshaping healthcare and AI investing, so compare it with 37 healthcare AI stocks . Tempus AI operates as a US healthcare technology business in the Life Sciences industry, which gives it a front-row seat in applying data and AI to clinical decision-making. That position helps explain why management is investing in a whole-genome platform that leans so heavily on linked medical records. 1 thing going right for Tempus AI that this headline doesn't cover. The 100,000 genome goal, with a path to one million, gives Tempus AI more depth in disease specific data that many pharma and AI groups want access to. A model ready dataset that links DNA, imaging, pathology and outcomes can support more use cases across...",
    "product": "whole-genome sequencing and clinical data platform",
    "summary": "Announced a new whole-genome sequencing initiative and platform linked to clinical data for AI research, with general availability planned for mid-2027.",
    "location": "United States",
    "planning": true,
    "image_url": "https://s.yimg.com/lo/mysterio/api/95b2ac7b6410dcff325e9a927ebf04331f7334b8260f63b24156f695de2ff6be/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fsimply_wall_st__316%2Ff9c5ca0dd17ca19906658734d1b51f73.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "whole-genome sequencing and clinical data platform",
      "full_text": "new whole-genome sequencing and clinical data platform",
      "fuzzy_match": false
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "future_tech",
      "data",
      "medical"
    ],
    "published_at": "2026-09-19T11:14:21Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-01",
    "article_sentence": "Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026."
  }
}

curl https://signals.autobound.ai/v1/signals/31782075-ab16-af29-be71-17c0ead894ef \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","limit":20}'